Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Comparison of the Safety and Efficacy of Volinanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties. A 4 Week, Randomized, Double-Blind, Comparative, Parallel-Group Study.

Trial Profile

Comparison of the Safety and Efficacy of Volinanserin and Lormetazepam in the Treatment of Insomnia Characterized by Sleep Maintenance Difficulties. A 4 Week, Randomized, Double-Blind, Comparative, Parallel-Group Study.

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Volinanserin (Primary) ; Lormetazepam
  • Indications Insomnia
  • Focus Therapeutic Use
  • Acronyms REST
  • Sponsors Sanofi

Most Recent Events

  • 08 Apr 2022 This trial has been completed in Spain (End Date: 30 Jan 2009) according to European Clinical Trials Database record.
  • 01 Apr 2022 This trial has been completed in France (End Date: 30 Jan 2009) according to European Clinical Trials Database record.
  • 27 Jun 2012 Additional location (Netherlands) added as reported by European Clinical Trials Database.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top